Janus Henderson Investors has launched Horizon Biotechnology fund. This Luxembourg domiciled SICAV will invest in innovative biotechnology and biotechnology-related companies that seek to address high unmet medical needs around the world.
The fund will target long-term growth within this fast growing and innovative sector. It will be co-managed by Andy Acker and Dan Lyons, who have more than 40 years of combined experience investing in biotechnology.
Ignacio de la Maza, head of Continental Europe, Wholesale & Latin America said: ‘We are launching the fund to meet the needs of those clients searching for additional opportunities to invest in biotechnology. The fund will be managed by a team of experts with extensive scientific backgrounds and supported by the larger Janus Henderson healthcare investment team.'